Drug Trial Radar · NCT03453112
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
494
Actual
Start
Oct 9, 2017
Primary completion
Dec 28, 2021
Study completion Dec 28, 2021
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire treatment period in average pre-dose morning peak expiratory flow \[PEF\]) in asthmatic patients. Secondary Objectives To evaluate the effect of the test treatments in terms of additional lung function parameters and clinical outcome measures, and to assess the safety and tolerability.
Conditions
- Asthma
Interventions
Foster 100/6µg NEXThalerDrug
A fixed combination of beclometasone dipropionate 100 µg and formoterol fumarate 6 µg per actuation, delivered via a breath-actuated dry powder inhaler (DPI).
Foster 100/6µg pMDIDrug
A fixed combination of beclometasone dipropionate 100 µg and formoterol fumarate 6 µg per actuation, delivered via a pressurized metered-dose inhaler (pMDI) with HFA\_134a propellant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment Period in Average Pre-dose Morning Peak Expiratory Flow (PEF)Time frame: Baseline (Week 0, Visit 3) and Week 12 (EoT)
Locations
51 sites in 1 country. Site status is shown where the registry gives one.
Chiesi Clinical Trial site 15672
Beijing, China
Chiesi clinical Trial site 15636
Beijing, China
Chiesi Clinical Trial site 15638
Chongqing, China
Chiesi Clinical Trial site 15670
Guizhou, China
Chiesi clinical Trial Site 15611
Hebei, China
Chiesi Clinical trial site 15660
Jilin City, China
Chiesi Clinical Trial site 15628
Shanghai, China
Chiesi clinical trial site 15637
Shanghai, China
Chiesi Clinical Trial site 15666
Shenzhen, China
Chiesi clinical Trial site 15633
Sichuan, China
Chiesi Clinical Trial site 15669
Ürümqi, China
Chiesi Clinical Trial site 15641
Hefei, Anhui, China
Chiesi Clinical Trial site 15682
Beijing, Beijing Municipality, China
Chiesi Clinical Trial site 15663
Beijing, Beijing Municipality, China
Chiesi Clinical Trial site 15662
Foshan, Guangdong, China
Chiesi Clinical Trial site 15671
Guangzhou, Guangdong, China
Chiesi clinical Trial Site 15610
Guangzhou, Guangdong, China
Chiesi clinical Trial site 15656
Guangzhou, Guangdong, China
Chiesi Clinical Trial site 15668
Guangzhou, Guangdong, China
Chiesi Clinical Trial site 15677
Huizhou, Guangdong, China
Chiesi Clinical Trial site 15683
Shenzhen, Guangdong, China
Chiesi Clinical Trial site 15608
Shenzhen, Guangdong, China
Chiesi Clinical Trial site 15607
Zhanjiang, Guangdong, China
Chiesi Clinical Trial site 15610
Guangzhou, Guangzhou, China
Chiesi Clinical Trial site 15673
Haikou, Hainan, China
Chiesi Clinical Trial site 15678
Qiqihar, Heilongjiang, China
Chiesi Clinical Trial site 15681
Xinxiang, Henan, China
Chiesi Clinical Trial site 15679
Zhengzhou, Henan, China
Chiesi Clinical Trial site 15614
Wuhan, Hubei, China
Chiesi Clinical Trial site 15661
Wuhan, Hubei, China
Chiesi Clinical Trial site 15675
Hengyang, Hunan, China
Chiesi Clinical Trial site 15643
Changzhou, Jiangsu, China
Chiesi Clinical Trial site 15674
Pingxiang, Jiangxi, China
Chiesi Clinical Trial site 15676
Jilin City, Jilin, China
Chiesi clinical Trial site 15621
Shenyang, Liaoning, China
Chiesi clinical Trial site 15619
Nanchang, Nanchang, China
Chiesi Clinical Trial site 15650
Hohhot, Neimenggu, China
Chiesi clinical Trial site 15659
Hohhot, Neimenggu, China
Chiesi Clinical Trial site 15630
Shanghai, Shanghai Municipality, China
Chiesi Clinical Trial site 15664
Shanghai, Shanghai Municipality, China
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.